Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma

• Published in: Journal of allergy and clinical immunology 1996-04, Vol.97 (4), p.938-946
• Main Authors: Verberne, Anja A.P.H., Hop, Wim C.J., Creyghton, Florence B.M., van Rooij, Rosemarie W.G., van den Berg, Marcel, de Jongste, Johan C., Kerrebijn, Karel F.
• Format: Article
• Language: English
• Subjects: Adolescent; Airway Resistance - drug effects; airway responsiveness; Albuterol - administration & dosage; Albuterol - adverse effects; Albuterol - analogs & derivatives; Albuterol - therapeutic use; asthma; Asthma - chemically induced; Asthma - drug therapy; Asthma - physiopathology; Biological and medical sciences; Bronchoconstriction - drug effects; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - adverse effects; Bronchodilator Agents - therapeutic use; Child; children; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Medical sciences; Pharmacology. Drug treatments; Respiratory system; salbutamol; Salmeterol; Salmeterol Xinafoate
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/S0091-6749(96)80068-6

Background: Inhalation of a single dose of the long-acting ß 2-adrenoceptor agonist salmeterol protects against methacholine-induced airway obstruction and other bronchoconstricting stimuli for at least 12 hours. Hypothetically, twice daily dosing of salmeterol may result in continuous protection. Objective: This study was designed to investigate the protective effect of a single dose of salmeterol and of continuous twice daily treatment on airway responsiveness to methacholine. Methods: In a double-blind, parallel study, salmeterol 50 μg twice daily was compared with salbutamol 200 μg twice daily. Thirty children with mild asthma, who had little or no bronchial obstruction and were hyperresponsive to methacholine (PD 20≤150 μg) were allocated to receive either salmeterol or salbutamol. Airway responsiveness was measured before study entry, 12 hours after a single dose of drug was given, and monthly during 4 months of daily treatment. Measurements were always performed at the same time of the day, 12 hours after the last dose of medication was administered. Results: No significant differences in FEV 1 were found between treatments at any time point. PD 20 significantly increased after the first dose of salmeterol was given (geometric mean, 100 μg). Geometric mean PD 20 values were significantly better during salmeterol treatment than during salbutamol treatment, 52 and 25 μg, respectively (p=0.005). Conclusion: The protection provided by salmeterol during maintenance treatment was less than that provided after the first dose (p